⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Disc Medicine, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disc Medicine, Inc.
↗Watertown, Massachusetts, USA
Disc Medicine is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company focuses on modifying fundamental biological pathways associated with red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Headquartered in Watertown, Massachusetts, the company is building a portfolio of first-in-class therapeutic candidates. Its lead asset, bitopertin, is being developed for erythropoietic porphyrias, including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), as well as Diamond-Blackfan Anemia (DBA).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$0
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Foresite Capital
STOCK
Exchange:NASDAQ
Ticker:IRON
Market Cap:$2.51B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule, Biologic
Active Trials:3
Trial Phases:Phase 1: 1 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Roche (Licensing agreement for bitopertin)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
John Quisel - President and CEO
LINKS
Website:discmedicine.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Disc Medicine, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.